InsiderTrades

Form 4 for BIIB Biogen

Accepted 2026-02-10 00:00:00 ET · period of report 2026-02-06 · accession 0000875045-26-000020 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-02-10 2026-02-06 BIIB Keeney Adam Head of Corp. Development F - Tax $201.18 -1,583 3,597 -31% -$318.5K
DM 2026-02-10 2026-02-06 BIIB Keeney Adam Head of Corp. Development M - OptEx $0.00 +5,080 4,186 New $0
DM 2026-02-10 2026-02-06 BIIB Keeney Adam Head of Corp. Development M - OptEx $0.00 -5,080 6,557 -44% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-02-06 F D 994 $201.18 5,881 D — —
2 Common Common Stock 2026-02-06 M A 3,278 $0.00 6,875 D — —
3 Common Common Stock 2026-02-06 M A 1,802 $0.00 4,186 D — —
4 Common Common Stock 2026-02-06 F D 589 $201.18 3,597 D — —
5 Derivative Restricted Stock Unit 2026-02-06 M D 1,802 $0.00 1,802 D $0.00 · — to 2027-02-07 1,802 Common Stock (F1) The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.
6 Derivative Restricted Stock Unit 2026-02-06 M D 3,278 $0.00 6,557 D $0.00 · — to 2028-02-06 3,278 Common Stock (F2) The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.